Welcome to our dedicated page for VERADERMICS SEC filings (Ticker: MANE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on VERADERMICS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into VERADERMICS's regulatory disclosures and financial reporting.
Veradermics, Incorporated completed an underwritten public offering of 3,843,790 shares of common stock at $100.00 per share, using its effective Form S-1 registration statements. The underwriters also received a 30-day option to buy up to an additional 576,568 shares at the same public price, less fees.
At the same time, Veradermics closed a private placement of pre-funded warrants to Suvretta Capital–affiliated investors, covering 300,000 shares of common stock at $99.99999 per warrant, for gross proceeds of about $30.0 million before costs. Each pre-funded warrant carries a nominal exercise price of $0.00001 per share, can be exercised in cash or cashlessly, and remains outstanding until fully exercised.
The warrants include a beneficial ownership limitation that blocks exercises above 9.99% of Veradermics’ common stock, with the ability for a holder to adjust the cap up to 19.99% effective on the 61st day after notice. The company agreed to customary covenants in the Securities Purchase Agreement, including restrictions on additional equity issuances for 90 days, subject to exceptions.
Veradermics is offering 3,843,790 shares of common stock at $100.00 per share to raise gross proceeds of $384,379,000. The company concurrently agreed to sell pre-funded warrants in a private placement (PIPE) for 300,000 shares at $99.99999 each to affiliates of Suvretta Capital; those pre-funded warrants are immediately exercisable, subject to ownership limits. Net proceeds from the offering and PIPE are estimated at approximately $388.8 million (or $443.0 million if the underwriters’ option is fully exercised), which the company intends to use for commercial launch activities, manufacturing expansion, clinical development and general corporate purposes.
Veradermics is registering 3,350,000 shares of common stock or pre-funded warrants in a primary offering, alongside a concurrent private placement (PIPE), with the aggregate securities issued across both remaining 3,350,000. The company develops VDPHL01, an extended‑release oral minoxidil candidate for pattern hair loss in men and women. A Phase 2/3 trial in 519 men met all primary and key secondary endpoints, with VDPHL01 achieving 30.3 and 33.0 non‑vellus hairs/cm² increases versus 7.3 for placebo and high rates of patient‑reported improvement. Treatment was generally well tolerated without treatment‑related serious cardiac events. Veradermics estimates net proceeds of about $212.9 million from the offering and PIPE, assuming a $67.84 share price, and reported preliminary cash, cash equivalents and marketable securities of approximately $390.8 million as of March 31, 2026. Together, this capital is expected to fund operations into 2030, including commercialization preparation for VDPHL01 if approved.
Veradermics is registering 3,350,000 shares of common stock or pre-funded warrants in a primary offering, alongside a concurrent private placement (PIPE), with the aggregate securities issued across both remaining 3,350,000. The company develops VDPHL01, an extended‑release oral minoxidil candidate for pattern hair loss in men and women. A Phase 2/3 trial in 519 men met all primary and key secondary endpoints, with VDPHL01 achieving 30.3 and 33.0 non‑vellus hairs/cm² increases versus 7.3 for placebo and high rates of patient‑reported improvement. Treatment was generally well tolerated without treatment‑related serious cardiac events. Veradermics estimates net proceeds of about $212.9 million from the offering and PIPE, assuming a $67.84 share price, and reported preliminary cash, cash equivalents and marketable securities of approximately $390.8 million as of March 31, 2026. Together, this capital is expected to fund operations into 2030, including commercialization preparation for VDPHL01 if approved.
Veradermics, Incorporated reports a preliminary unaudited balance of cash, cash equivalents and marketable securities of about $390.8 million as of March 31, 2026.
The figure was prepared by management and is subject to the company’s normal financial closing procedures, so the final amount in the unaudited condensed consolidated financial statements for the three months ended March 31, 2026 may differ materially. The company notes that Deloitte & Touche LLP has not audited, reviewed, examined, compiled or applied agreed-upon procedures to this preliminary data and therefore does not provide any assurance on it.
Veradermics, Incorporated reports a preliminary unaudited balance of cash, cash equivalents and marketable securities of about $390.8 million as of March 31, 2026.
The figure was prepared by management and is subject to the company’s normal financial closing procedures, so the final amount in the unaudited condensed consolidated financial statements for the three months ended March 31, 2026 may differ materially. The company notes that Deloitte & Touche LLP has not audited, reviewed, examined, compiled or applied agreed-upon procedures to this preliminary data and therefore does not provide any assurance on it.
Veradermics, Inc. reported positive topline results from its Phase 2/3 Study ‘302’ of oral VDPHL01 in 519 men with mild-to-moderate pattern hair loss. The trial met all primary and key secondary endpoints, with once-daily and twice-daily doses showing significantly greater hair growth than placebo.
At Month 6, non‑vellus target area hair count increased by 30.3 hairs/cm² with once-daily VDPHL01 and 33.0 hairs/cm² with twice-daily dosing, versus 7.3 hairs/cm² for placebo. Patient-reported ‘improved’ or ‘much improved’ outcomes reached 48.4% and 62.9% in the active arms compared with 13.4% on placebo.
Any improvement in hair coverage was reported by 79.3% and 86.0% of VDPHL01 patients versus 35.6% on placebo, and investigators graded 72.0% and 84.4% of active-arm patients as improved. VDPHL01 was generally well tolerated, with no treatment-related serious adverse events or cardiac adverse events of special interest and treatment-emergent adverse event rates similar to placebo.
Veradermics, Inc. reported positive topline results from its Phase 2/3 Study ‘302’ of oral VDPHL01 in 519 men with mild-to-moderate pattern hair loss. The trial met all primary and key secondary endpoints, with once-daily and twice-daily doses showing significantly greater hair growth than placebo.
At Month 6, non‑vellus target area hair count increased by 30.3 hairs/cm² with once-daily VDPHL01 and 33.0 hairs/cm² with twice-daily dosing, versus 7.3 hairs/cm² for placebo. Patient-reported ‘improved’ or ‘much improved’ outcomes reached 48.4% and 62.9% in the active arms compared with 13.4% on placebo.
Any improvement in hair coverage was reported by 79.3% and 86.0% of VDPHL01 patients versus 35.6% on placebo, and investigators graded 72.0% and 84.4% of active-arm patients as improved. VDPHL01 was generally well tolerated, with no treatment-related serious adverse events or cardiac adverse events of special interest and treatment-emergent adverse event rates similar to placebo.
Veradermics, Incorporated is a late clinical-stage biopharmaceutical company focused on treating pattern hair loss (PHL) in men and women. Its lead candidate, VDPHL01, is an extended‑release oral form of minoxidil designed to boost hair growth while limiting cardiac side effects.
The company is running three registration-directed, placebo-controlled trials: two in male PHL patients using an 8.5 mg dose and one in female patients using a 4.5 mg dose, with all male trials fully enrolled. Early Phase 2 data in men showed faster, more consistent and denser hair regrowth versus historical topical and immediate‑release oral minoxidil, with 90.5% of patients reporting improved hair coverage at four months and generally good tolerability.
Veradermics estimates the current U.S. PHL treatment market at about $9 billion annually and plans a cash-pay, multi‑channel commercial strategy centered on dermatologists, direct‑to‑consumer advertising, social media and telehealth. The company intends to seek U.S. approval for VDPHL01 through the 505(b)(2) pathway and holds patents expected to extend into at least 2043, but highlights substantial ongoing losses, dependence on VDPHL01’s success, the need for additional financing, competitive pressures and significant clinical, regulatory and commercialization risks.
Veradermics, Inc. reported a larger net loss for the fourth quarter and full year 2025 as it accelerated late-stage development of its oral hair-loss candidate VDPHL01 and prepared to go public. Net loss was $21.8 million for the quarter and $70.0 million for 2025, compared with $5.7 million and $26.5 million in 2024.
Research and development spending more than doubled to $62.1 million in 2025, and general and administrative costs also rose as the company scaled its organization. Cash, cash equivalents and marketable securities were $141.9 million at December 31, 2025, before an upsized IPO in February 2026 that raised approximately $294.8 million in gross proceeds, which the company expects will fund operations into 2029, including multiple Phase 3 readouts and a potential launch of VDPHL01 if approved.
Veradermics, Inc director John W. Childs, through the John W. Childs 2013 Revocable Trust, indirectly bought 294,117 shares of Common Stock at $17.00 per share in an open‑market purchase. This amended Form 4 corrects the earlier report by clarifying that the shares are held via the revocable trust rather than J.W. Childs Associates (FL), L.P.
Veradermics, Incorporated disclosed that venture funds affiliated with Longitude Capital and managing members Patrick G. Enright and Juliet Tammenoms Bakker have filed a Schedule 13D reporting a significant stake in its common stock. The Reporting Persons beneficially own 4,653,873 shares of common stock, representing 12.5% of the outstanding shares based on 37,339,464 shares outstanding as of February 5, 2026.
Longitude Venture Partners V, L.P. holds 2,600,399 shares, and Longitude 103.8 East, L.P. holds 2,053,474 shares, with voting and dispositive power shared through their general partners. These positions arose from investments in Veradermics’ Series B and Series C preferred stock and additional common shares purchased at $17.00 per share in the initial public offering. The investors state they hold the shares for general investment purposes, may increase or decrease their holdings over time, and are subject to a 180‑day lock-up following the IPO underwriting agreement.